Russell 2000 Index Newsroom

Ligand Pharmaceuticals Analyst Ratings

Benzinga4minutes ago

RBC Capital Reiterates Outperform on Ligand Pharmaceuticals, Maintains $130 Price Target

Benzinga5minutes ago

RBC Capital Maintains Outperform on NCR Voyix, Lowers Price Target to $16

Benzinga8minutes ago

JP Morgan Maintains Overweight on AnaptysBio, Raises Price Target to $75

Benzinga12minutes ago

Pactiv Evergreen Analyst Ratings

Benzinga12minutes ago

Vivid Seats Price Target Cut to $7.00/Share From $8.00 by RBC Capital

Dow Jones12minutes ago

RBC Capital Maintains Outperform on Pactiv Evergreen, Lowers Price Target to $13

Benzinga13minutes ago

Canaccord Genuity Upgrades Rapid7 to Buy From Hold, Adjusts Price Target to $43 From $52

MT Newswires13minutes ago

MBIA Analyst Ratings

Benzinga17minutes ago

Agilon Health Price Target Maintained With a $8.00/Share by RBC Capital

Dow Jones17minutes ago

V2X Analyst Ratings

Benzinga18minutes ago

Buy Rating Affirmed for International Money Express Amid Digital Growth and Valuation Opportunity

TipRanks21minutes ago

RBC Capital Reiterates Outperform on V2X, Maintains $55 Price Target

Benzinga21minutes ago

Agilon Health Analyst Ratings

Benzinga23minutes ago

Xenia Hotels & Resorts Analyst Ratings

Benzinga30minutes ago

Beam Therapeutics Price Target Cut to $31.00/Share From $33.00 by Barclays

Dow Jones30minutes ago

Applied Optoelectronics Price Target Cut to $9.00/Share From $12.00 by B. Riley Securities

Dow Jones34minutes ago

Buy Rating Affirmed on Adtran Despite Industry Challenges and Revenue Dip, Highlighting Long-Term Growth Potential

TipRanks41minutes ago

Applied Optoelectronics Analyst Ratings

Benzinga43minutes ago

Goldman Sachs Maintains Neutral on TG Therapeutics, Raises Price Target to $20

Benzinga58minutes ago